Related Experiment Video
Updated: Jul 17, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Biomarkers for monitoring antiangiogenic therapy
Rupal S Bhatt1, Pankaj Seth, Vikas P Sukhatme
1Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA. rbhatt@bidmc.harvard.edu
Abstract:
A variety of antiangiogenic agents are currently available for the treatment of renal cell carcinoma. With these exciting new therapeutic agents comes the challenge of elucidating useful biomarkers to monitor patients receiving these therapies. Although many patients benefit from antiangiogenic therapies, it is often by achieving stability of their disease. Thus, development of noninvasive biomarkers of disease response and relapse is a crucial objective to aid in the management of patients. The current technologies being explored in this field include circulating plasma proteins, cells, and nucleic acids and novel imaging techniques. Surrogate markers of angiogenesis could help with selecting patients for therapy, determining optimal dosing of therapy, deciding whether to change therapy, and assessing appropriate salvage therapy.
Insights
Identifying noninvasive biomarkers is crucial for monitoring patients undergoing antiangiogenic therapy for renal cell carcinoma. These biomarkers will aid in treatment selection, dosing, and assessing patient response to therapy.
Area of Science:
- Oncology
- Biomarkers
- Medical Imaging
Background:
- Antiangiogenic agents are available for renal cell carcinoma (RCC) treatment.
- Monitoring patient response to these therapies is challenging.
- Disease stability is a common outcome, necessitating relapse monitoring.
Purpose of the Study:
- To highlight the need for noninvasive biomarkers in RCC management.
- To discuss current and emerging technologies for biomarker discovery.
- To emphasize the role of biomarkers in optimizing antiangiogenic therapy.
Main Methods:
- Review of current antiangiogenic therapies for RCC.
- Exploration of noninvasive biomarker technologies.
- Discussion of circulating biomarkers (plasma proteins, cells, nucleic acids).
- Consideration of novel imaging techniques.
Main Results:
- Noninvasive biomarkers are essential for patient management.
- Circulating biomarkers and advanced imaging show promise.
- Biomarkers can guide therapy selection, dosing, and adjustments.
Conclusions:
- Development of noninvasive biomarkers is a crucial objective for RCC patients.
- Surrogate markers of angiogenesis can significantly aid clinical decision-making.
- Biomarkers will improve patient selection, treatment optimization, and salvage therapy assessment.
